share_log

8-K/A: Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (Amendment)

8-K/A: Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (Amendment)

8-K/A：Cassava Sciences報告2024年第二季度財務業績和運營最新情況(修正)
美股SEC公告 ·  08/09 08:27

Moomoo AI 已提取核心訊息

Cassava Sciences, Inc. has filed an amendment to its previously furnished Form 8-K report, originally submitted on August 8, 2024. The amendment, dated August 9, 2024, corrects an error in the diluted Net income (loss) per share for the six months ended June 30, 2024. The initial report incorrectly stated the figure as $(1.72), whereas the amended report presents the correct figure of $(0.28). This figure aligns with the data provided in the Company's quarterly report on Form 10-Q for the same period. The amendment clarifies that no other figures or information from the initial report are affected. The corrected financial information is furnished and not filed, meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into any future filings under the Securities Act of 1933 or the Exchange Act.
Cassava Sciences, Inc. has filed an amendment to its previously furnished Form 8-K report, originally submitted on August 8, 2024. The amendment, dated August 9, 2024, corrects an error in the diluted Net income (loss) per share for the six months ended June 30, 2024. The initial report incorrectly stated the figure as $(1.72), whereas the amended report presents the correct figure of $(0.28). This figure aligns with the data provided in the Company's quarterly report on Form 10-Q for the same period. The amendment clarifies that no other figures or information from the initial report are affected. The corrected financial information is furnished and not filed, meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into any future filings under the Securities Act of 1933 or the Exchange Act.
Cassava Sciences提交了對其先前提交的2024年8月8日提交的8-K表單報告的修訂。這份於2024年8月9日的修訂糾正了截至2024年6月30日六個月的每股稀釋淨利潤（虧損）的錯誤。初始報告錯誤地將數字聲明爲（1.72）美元，而修訂後的報告呈現了正確的數字（0.28）美元。此數字與該公司同一時期提交的10-Q表格季度報告中提供的數據相一致。修訂澄清了初始報告中沒有其他數字或信息受到影響。修正後的財務信息是提交而非註冊，這意味着它不受《1934年證券交易法》第18條的責任約束，也不會被納入到任何未來根據《1933年證券法》或《交易法》提交的文件中。
Cassava Sciences提交了對其先前提交的2024年8月8日提交的8-K表單報告的修訂。這份於2024年8月9日的修訂糾正了截至2024年6月30日六個月的每股稀釋淨利潤（虧損）的錯誤。初始報告錯誤地將數字聲明爲（1.72）美元，而修訂後的報告呈現了正確的數字（0.28）美元。此數字與該公司同一時期提交的10-Q表格季度報告中提供的數據相一致。修訂澄清了初始報告中沒有其他數字或信息受到影響。修正後的財務信息是提交而非註冊，這意味着它不受《1934年證券交易法》第18條的責任約束，也不會被納入到任何未來根據《1933年證券法》或《交易法》提交的文件中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間